Arbutus Biopharma Corporation
US ˙ NasdaqGS ˙ CA03879J1003

Introduction

This page provides a comprehensive analysis of the known insider trading history of David C Hastings. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate David C Hastings has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:SCYX / SCYNEXIS, Inc. Director 69,183
US:ABUS / Arbutus Biopharma Corporation Chief Financial Officer 249,824
US:ETTX / Entasis Therapeutics Holdings Inc Director 0
US:UNIS / Unilife Corp See Remarks 150,000
US:INCY / Incyte Corporation Chief Financial Officer 33,375
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by David C Hastings. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ABUS / Arbutus Biopharma Corporation - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ABUS / Arbutus Biopharma Corporation. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ABUS / Arbutus Biopharma Corporation Insider Trades
Insider Sales ABUS / Arbutus Biopharma Corporation - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ABUS / Arbutus Biopharma Corporation. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ABUS / Arbutus Biopharma Corporation Insider Trades
Insider Purchases SCYX / SCYNEXIS, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ABUS / Arbutus Biopharma Corporation. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2018-03-08 SCYX HASTINGS DAVID C 11,834 1.6900 1,183 16.9000 19,999 126 20.1 3,779 18.90
2017-06-21 SCYX HASTINGS DAVID C 20,000 1.7500 2,000 17.5000 35,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SCYX / SCYNEXIS, Inc. Insider Trades
Insider Sales SCYX / SCYNEXIS, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ABUS / Arbutus Biopharma Corporation. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SCYX / SCYNEXIS, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by David C Hastings as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-06-30 2025-06-26 4 SCYX SCYNEXIS INC
Common Stock
A - Award 23,000 69,183 49.80
2025-02-19 2025-02-14 4 ABUS Arbutus Biopharma Corp
Common Shares
A - Award 90,100 249,824 56.41
2025-02-05 2025-02-04 4 ABUS Arbutus Biopharma Corp
Common Shares
S - Sale X -22,183 159,724 -12.19 3.28 -72,827 524,374
2024-06-21 2024-06-20 4 SCYX SCYNEXIS INC
Common Stock
A - Award 23,000 46,183 99.21
2024-02-05 2024-02-02 4 ABUS Arbutus Biopharma Corp
Common Shares
S - Sale X -9,593 181,907 -5.01 2.31 -22,184 420,660
2024-02-05 2024-02-01 4 ABUS Arbutus Biopharma Corp
Common Shares
A - Award 112,500 191,500 142.41
2023-06-23 2023-06-15 4 SCYX SCYNEXIS INC
Common Stock
A - Award 10,000 23,183 75.86
2023-02-03 2023-02-01 4 ABUS Arbutus Biopharma Corp
Common Shares
A - Award 79,000 79,000
2022-07-11 2022-07-11 4 ETTX Entasis Therapeutics Holdings Inc.
Common Stock
D - Sale to Issuer -27,500 0 -100.00 2.20 -60,500
2022-07-11 2022-07-07 4 ETTX Entasis Therapeutics Holdings Inc.
Common Stock
U - Other -22,000 0 -100.00 2.20 -48,400
2022-06-22 2022-06-17 4 SCYX SCYNEXIS INC
Common Stock
A - Award 10,000 13,183 314.17
2022-02-15 2021-07-16 4 ETTX Entasis Therapeutics Holdings Inc.
Stock Option (Right to Buy)
A - Award 5,769 5,769
2022-02-15 2021-07-16 4 ETTX Entasis Therapeutics Holdings Inc.
Stock Option (Right to Buy)
D - Sale to Issuer -7,500 0 -100.00
2022-02-15 2021-07-16 4 ETTX Entasis Therapeutics Holdings Inc.
Stock Option (Right to Buy)
A - Award 11,538 11,538
2022-02-15 2021-07-16 4 ETTX Entasis Therapeutics Holdings Inc.
Stock Option (Right to Buy)
D - Sale to Issuer -15,000 0 -100.00
2022-02-15 2021-07-16 4 ETTX Entasis Therapeutics Holdings Inc.
Stock Option (Right to Buy)
A - Award 9,276 9,276
2022-02-15 2021-07-16 4 ETTX Entasis Therapeutics Holdings Inc.
Stock Option (Right to Buy)
D - Sale to Issuer -12,060 0 -100.00
2022-01-20 2022-01-20 4 ABUS Arbutus Biopharma Corp
Stock Option (Right to Buy)
A - Award 285,000 285,000 2.81 800,850 800,850
2022-01-19 2022-01-18 4 ETTX Entasis Therapeutics Holdings Inc.
Common Stock
A - Award 27,500 49,500 125.00
2021-06-21 2021-06-16 4 SCYX SCYNEXIS INC
Stock Option (Right to Buy)
A - Award 10,000 10,000
2021-04-02 2021-04-01 4 ETTX Entasis Therapeutics Holdings Inc.
Common Stock
A - Award 22,000 22,000
2021-03-31 2020-07-06 4/A SCYX SCYNEXIS INC
Stock Option (Right to Buy)
A - Award 55,000 55,000
2021-02-17 2021-02-13 4 ABUS Arbutus Biopharma Corp
Stock Options
A - Award 250,000 250,000
2020-10-06 2020-06-10 4 ETTX Entasis Therapeutics Holdings Inc.
Stock Option (Right to Buy)
A - Award 11,000 11,000
2020-07-08 2020-07-06 4 SCYX SCYNEXIS INC
Stock Option (Right to Buy)
A - Award 45,000 45,000
2020-02-19 2020-02-17 4 ABUS Arbutus Biopharma Corp
Stock Options
A - Award 100,000 100,000
2019-06-21 2019-06-19 4 ETTX Entasis Therapeutics Holdings Inc.
Stock Option (Right to Buy)
A - Award 7,500 7,500
2019-06-20 2019-06-18 4 SCYX SCYNEXIS INC
Stock Option (Right to Buy)
A - Award 45,000 45,000
2019-03-05 2019-03-01 4 ABUS Arbutus Biopharma Corp
Employee Stock Option (Right to Buy)
A - Award 137,500 137,500
2019-01-22 2019-01-18 4 ETTX Entasis Therapeutics Holdings Inc.
Stock Option (right to buy)
A - Award 15,000 15,000
2019-01-04 2019-01-02 4 SCYX SCYNEXIS INC
Stock Option (right to buy)
A - Award 22,500 22,500
2018-06-21 2018-06-19 4 ABUS Arbutus Biopharma Corp
Employee Stock Option (Right to Buy)
A - Award 200,000 200,000
2018-03-12 2018-03-08 4 SCYX SCYNEXIS INC
Common Stock Warrant (right to buy)
P - Purchase 5,325 5,325
2018-03-12 2018-03-08 4 SCYX SCYNEXIS INC
Common Stock Warrant (right to buy)
P - Purchase 8,875 8,875
2018-03-12 2018-03-08 4 SCYX SCYNEXIS INC
Common Stock
P - Purchase 11,834 31,834 59.17 1.69 19,999 53,799
2018-01-04 2018-01-02 4 SCYX SCYNEXIS INC
Stock Option (right to buy)
A - Award 19,989 19,989
2017-06-22 2017-06-21 4 SCYX SCYNEXIS INC
Common Stock
P - Purchase 20,000 20,000 1.75 35,000 35,000
2017-01-30 2017-01-26 4 UNIS Unilife Corp
Stock Option (Right to Buy)
A - Award 150,000 150,000
2017-01-05 2017-01-03 4 SCYX SCYNEXIS INC
Stock Option (right to buy)
A - Award 14,499 14,499
2016-06-06 2016-06-02 4 SCYX SCYNEXIS INC
Stock Option (right to buy)
A - Award 8,800 8,800 3.98 35,024 35,024
2015-09-28 2015-09-24 4 SCYX SCYNEXIS INC
Stock Option (right to buy)
A - Award 11,700 11,700
2015-02-25 2015-02-23 4 UNIS Unilife Corp
Common Stock
A - Award 300,000 300,000
2014-06-06 2014-06-05 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -50,000 33,375 -59.97
2014-06-06 2014-06-05 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -50,000 33,375 -59.97
2014-06-06 2014-06-05 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -23,966 30,430 -44.06
2014-06-06 2014-06-05 4 INCY INCYTE CORP
Common Stock
S - Sale -123,966 8,500 -93.58 52.81 -6,546,644 448,885
2014-06-06 2014-06-05 4 INCY INCYTE CORP
Common Stock
M - Exercise 50,000 132,466 60.63 5.46 273,000 723,264
2014-06-06 2014-06-05 4 INCY INCYTE CORP
Common Stock
M - Exercise 50,000 82,466 154.01 3.11 155,500 256,469
2014-06-06 2014-06-05 4 INCY INCYTE CORP
Common Stock
M - Exercise 23,966 32,466 281.95 9.41 225,520 305,505
2014-06-06 2014-06-04 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -18,534 54,396 -25.41
2014-06-06 2014-06-04 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -7,500 7,083 -51.43
2014-06-06 2014-06-04 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -43,500 35,817 -54.84
2014-06-06 2014-06-04 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -6,500 21,400 -23.30
2014-06-06 2014-06-04 4 INCY INCYTE CORP
Common Stock
S - Sale -76,034 8,500 -89.94 52.61 -4,000,149 447,185
2014-06-06 2014-06-04 4 INCY INCYTE CORP
Common Stock
M - Exercise 18,534 84,534 28.08 9.41 174,405 795,465
2014-06-06 2014-06-04 4 INCY INCYTE CORP
Common Stock
M - Exercise 7,500 66,000 12.82 13.34 100,050 880,440
2014-06-06 2014-06-04 4 INCY INCYTE CORP
Common Stock
M - Exercise 43,500 58,500 290.00 14.72 640,320 861,120
2014-06-06 2014-06-04 4 INCY INCYTE CORP
Common Stock
M - Exercise 6,500 15,000 76.47 17.79 115,635 266,850
2014-02-18 2014-02-18 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -32,001 0 -100.00
2014-02-18 2014-02-18 4 INCY INCYTE CORP
Common Stock
S - Sale -32,001 8,500 -79.01 65.64 -2,100,546 557,940
2014-02-18 2014-02-18 4 INCY INCYTE CORP
Common Stock
M - Exercise 32,001 40,501 376.48 8.99 287,689 364,104
2014-02-18 2014-02-14 4 INCY INCYTE CORP
Incentive Stock Option (right to buy)
M - Exercise -5,036 0 -100.00
2014-02-18 2014-02-14 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -34,964 32,001 -52.21
2014-02-18 2014-02-14 4 INCY INCYTE CORP
Common Stock
S - Sale -40,000 8,500 -82.47 64.74 -2,589,600 550,290
2014-02-18 2014-02-14 4 INCY INCYTE CORP
Common Stock
M - Exercise 5,036 48,500 11.59 8.99 45,274 436,015
2014-02-18 2014-02-14 4 INCY INCYTE CORP
Common Stock
M - Exercise 34,964 43,464 411.34 8.99 314,326 390,741
2014-02-18 2014-02-13 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -66,000 27,900 -70.29
2014-02-18 2014-02-13 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -90,335 0 -100.00
2014-02-18 2014-02-13 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -16,000 28,462 -35.99
2014-02-18 2014-02-13 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -13,000 79,317 -14.08
2014-02-18 2014-02-13 4 INCY INCYTE CORP
Incentive Stock Option (right to buy)
M - Exercise -9,665 0 -100.00
2014-02-18 2014-02-13 4 INCY INCYTE CORP
Incentive Stock Option (right to buy)
M - Exercise -7,999 5,036 -61.37
2014-02-18 2014-02-13 4 INCY INCYTE CORP
Common Stock
S - Sale -202,999 8,500 -95.98 66.12 -13,422,294 562,020
2014-02-18 2014-02-13 4 INCY INCYTE CORP
Common Stock
M - Exercise 66,000 211,499 45.36 17.79 1,174,140 3,762,567
2014-02-18 2014-02-13 4 INCY INCYTE CORP
Common Stock
M - Exercise 90,335 145,499 163.76 11.98 1,082,213 1,743,078
2014-02-18 2014-02-13 4 INCY INCYTE CORP
Common Stock
M - Exercise 16,000 55,164 40.85 18.32 293,120 1,010,604
2014-02-18 2014-02-13 4 INCY INCYTE CORP
Common Stock
M - Exercise 13,000 39,164 49.69 14.72 191,360 576,494
2014-02-18 2014-02-13 4 INCY INCYTE CORP
Common Stock
M - Exercise 9,665 26,164 58.58 11.98 115,787 313,445
2014-02-18 2014-02-13 4 INCY INCYTE CORP
Common Stock
M - Exercise 7,999 16,499 94.11 8.99 71,911 148,326
2014-01-23 2014-01-21 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
A - Award 23,379 23,379
2014-01-23 2014-01-21 4 INCY INCYTE CORP
Incentive Stock Option (right to buy)
A - Award 1,450 1,450
2013-09-09 2013-09-06 4 INCY INCYTE CORP
Incentive Stock Option (right to buy)
M - Exercise -5,556 0 -100.00
2013-09-09 2013-09-06 4 INCY INCYTE CORP
Non Qualified Stock Option (right to buy)
M - Exercise -94,444 0 -100.00
2013-09-09 2013-09-06 4 INCY INCYTE CORP
Common Stock
S - Sale -100,000 8,500 -92.17 35.16 -3,516,000 298,860
2013-09-09 2013-09-06 4 INCY INCYTE CORP
Common Stock
M - Exercise 5,556 108,500 5.40 7.09 39,392 769,265
2013-09-09 2013-09-06 4 INCY INCYTE CORP
Common Stock
M - Exercise 94,444 102,944 1,111.11 7.09 669,608 729,873
2013-02-20 2013-02-15 4 INCY INCYTE CORP
Incentive Stock Option (right to buy)
M - Exercise -60,000 0 -100.00
2013-02-20 2013-02-15 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -30,000 66,965 -30.94
2013-02-20 2013-02-15 4 INCY INCYTE CORP
Incentive Stock Option (right to buy)
M - Exercise -417 0 -100.00
2013-02-20 2013-02-15 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -9,583 0 -100.00
2013-02-20 2013-02-15 4 INCY INCYTE CORP
Common Stock
S - Sale -100,000 8,500 -92.17 22.52 -2,252,000 191,420
2013-02-20 2013-02-15 4 INCY INCYTE CORP
Common Stock
M - Exercise 60,000 108,500 123.71 5.12 307,200 555,520
2013-02-20 2013-02-15 4 INCY INCYTE CORP
Common Stock
M - Exercise 30,000 48,500 162.16 8.99 269,700 436,015
2013-02-20 2013-02-15 4 INCY INCYTE CORP
Common Stock
M - Exercise 417 18,500 2.31 8.19 3,415 151,515
2013-02-20 2013-02-15 4 INCY INCYTE CORP
Common Stock
M - Exercise 9,583 18,083 112.74 8.19 78,485 148,100
2013-02-12 2013-02-09 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
A - Award 44,462 44,462
2013-02-12 2013-02-09 4 INCY INCYTE CORP
Incentive Stock Option (right to buy)
A - Award 5,538 5,538
2012-01-23 2012-01-19 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
A - Award 93,900 93,900
2012-01-23 2012-01-19 4 INCY INCYTE CORP
Incentive Stock Option (right to buy)
A - Award 6,100 6,100
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)